Emmaus Life Sciences, Inc. — fact timeline

Emmaus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $12.5 million, net income net loss of $7.2 million, or $0.11 per share, EPS $0.11 per share.

“Net revenues for the year ended December 31, 2025 were $12.5 million”

Emmaus Life Sciences, Inc. entered into Exclusive Supply Agreement with NeoImmuneTech, Inc. (NIT) (effective 2026-03-02).

“n March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence”

Emmaus Life Sciences, Inc. entered into License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. valued at an upfront payment (effective 2025-12-24).

“On December 24, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, entered into a License and Exclusive Distribution Agreement, or License Agreement, dated as of the same day pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents, or the Products, in sickle cell disease, or the Field, in the U.S. and its territories and possession and Canada, referred to as the Territory, in exchange for an upfront payment and a royalty on NIT’s Product sales.”

Emmaus Life Sciences, Inc. incurred convertible notes of $600,000 at 10% maturing due on demand.

“On December 17, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share (the “Exchange Shares”) and a convertible promissory note in the principal amount of $600,000 (the “Exchange Note” and together with the Exchange Shares, the “Exchange Securities”) in exchange for the surrender for cancellation and satisfaction of the principal amount of an outstanding convertible promissory note currently due and payable in the principal amount of $3,000,000 (the “Subject Note”). The Subject Note bore interest at the annual rate of 10%, payable semi-annually, and was convertible at the election of the holder into shares of our common stock at the conversion price of $0.13 per share. The Exchange Note will bear interest at the annual rate of 10%, payabl”

Seah Lim resigned as director at Emmaus Life Sciences, Inc..

“On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.”

Jon Kuwahara was appointed as Director and Chair of Audit Committee at Emmaus Life Sciences, Inc..

“the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.”

George Sekulich was terminated as Chief Commercial Officer at Emmaus Life Sciences, Inc..

“in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024”

George Sekulich resigned as Director at Emmaus Life Sciences, Inc..

“On September 30, 2024, George Sekulich resigned as a member of the Board of Directors”

Willis Lee was appointed as Chief Executive Officer at Emmaus Life Sciences, Inc..

“On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.”